|
Synonyms: AMG 133 [3] | AMG-133 | AMG133
Compound class:
Antibody
Comment: Maridebart cafraglutide (AMG133) is an anti-human gastric inhibitory polypeptide receptor (GIPR) antagonist antibody-peptide conjugate [1,3]. It has two attached glucagon-like peptide 1 (GLP-1) agonist peptides (cafraglutide). Maridebart cafraglutide is proposed to ellicit synergistic effects (antagonism of GIPR signalling and activation of GLP-1 receptor signalling) to regulate body weight for application as an anti-obesity modality [2-3].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 12602 | maridebart cafraglutide |
| Synonyms |
|
| AMG 133 [3] | AMG-133 | AMG133 | |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 1408 |
| Other databases | |
| CAS Registry No. | 2760218-55-9 (source: WHO INN record) |
| GtoPdb PubChem SID | 496703286 |
| Search PubMed clinical trials | maridebart cafraglutide |
| Search PubMed titles | maridebart cafraglutide |
| Search PubMed titles/abstracts | maridebart cafraglutide |
